Pegvisomant and cabergoline combination therapy in acromegaly (Q46735065)

24 December 2017

title

Pegvisomant and cabergoline combination therapy in acromegaly (English)

1 reference

24 December 2017

author name string

I Bernabeu

1 reference

24 December 2017

C Alvarez-Escolá

1 reference

24 December 2017

A E Paniagua

1 reference

24 December 2017

T Lucas

1 reference

24 December 2017

I Pavón

1 reference

24 December 2017

J M Cabezas-Agrícola

1 reference

24 December 2017

F F Casanueva

1 reference

24 December 2017

M Marazuela

1 reference

24 December 2017

publication date

1 March 2013

1 reference

24 December 2017

published in

Pituitary

1 reference

24 December 2017

volume

1 reference

24 December 2017

issue

1 reference

24 December 2017

page(s)

101-108

1 reference

24 December 2017

Pituitary tumours: acromegaly

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

ACROSTUDY: the first 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Place of cabergoline in acromegaly: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Resistance to Somatostatin Analogs in Acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Radiotherapy and radiosurgery in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Clinical use of cabergoline as primary and adjunctive treatment for acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Factors regulating growth hormone secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-012-0382-Z

The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly

21 January 2018

1 reference

12 December 2020

The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly

1 reference

12 December 2020

Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly

1 reference

12 December 2020

Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients

1 reference

12 December 2020

Remission of acromegaly following long-term therapy with cabergoline: report of two cases

1 reference

12 December 2020

Decreased plasma growth hormone (GH) levels in acromegalics following CB 154(2-Br-alpha ergocryptine) administration

1 reference

12 December 2020

Long-term effects of pegvisomant in patients with acromegaly

1 reference

12 December 2020

10.1007/S11102-012-0382-Z

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017